AN UPDATE ON NEUROPATHIC PAIN MODELS

  • Seema Thakur Assistant Professor, Faculty of Pharmaceutical Sciences, PCTE Group of Institutes, Near, Baddowal Cantt. Ferozepur Road, Ludhiana, 142021, Punjab, 142021
  • Neha Srivastava

Abstract

An rodent animal model of pain offers a powerful tool in order to understand the mechanism involved in peripheral nerve injury for preclinical study of pain. A battery of neuropathic pain models has been developed to simulate the clinical pain conditions with diverse etiology. This article reviews some of the most widely used or promising new models for chronic pain. Partial spinal ligation, chronic constriction injury, and L5/l6 spinal nerve ligation represent three of the best-characterized rodent models of peripheral neuropathy. For reasons of reproducibility and simplicity, most studies of neuropathic pain are based upon animal models of traumatic nerve injury, usually in the rat sciatic nerve. The present review exhaustively discusses the methodology, behavioral alterations of different animal models of neuropathic pain along with their modiï¬cations. Development of these models has contributed immensely in understanding the chronic pain and underlying peripheral as well as central pathogenic mechanisms.

Keywords: Peripheral neuropathy, Neuropathic pain, Chronic constriction injury, Spinal nerve ligation, Partial sciatic nerve ligation

Keywords: Peripheral neuropathy, neuropathic pain, chronic constriction injury, spinal nerve ligation, partial sciatic nerve ligation.

Downloads

Download data is not yet available.

References

1. Merskey H, Bogduk N. Classification of chronic pain. Seattle: IASP Press; 1994.
2. Bennett GJ, Xie YK. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 1988;33:87-107.
3. Attal N, Jazat F, Kayser V, Guilbaud G. Further evidence for ‘pain-related’ behaviours in a model of unilateral peripheral mononeuropathy. Pain 1990;41:235–51.
4. Ling B, Coudore-Civiale MA, Balayssac D, Eschalier A, Coudore F, Authier N. Behavioral and immunohistological assessment of painful neuropathy induced by single oxaliplatin injection in the rat. Toxicology 2007;234:176-84.
5. Seltzer Z, Dubner R, Shir Y. A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury. Pain 1990;43:205–18.
6. Hargreaves K, Dubner R, Brown F, Flores C, Joris J. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 1988;32:77–88.
7. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 1994;53:55–3.
8. Kontinen VK, Meert TF. Predictive validity of neuropathic pain models in pharmacological studies with a behavioral outcome in the rat: a systematic review. Proceeding of the 10th world congress on Pain, Progress in Pain Research and Management. IASP Press; 2003;24:489-98.
9. Kim SH, Chung JM. An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 1992;50L:355–63.
10. Xu JT, Tu HY, Xin WJ, Liu XG, Zhang GH, Zhai CH. Activation of phosphatidylinositol 3-kinase and protein kinase B/Akt in dorsal root ganglia and spinal cord contributes to the neuropathic pain induced by spinal nerve ligation in rats. Exp Neurol 2007;206:269-79.
11. Znaor S, Lovric S, Hogan Q, Sapunar D. Association of neural inflammation with hyperalgesia following spinal nerve ligation. Croat Med J 2007;48:35-42.
12. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 1994;53:55–63.
13. Kim JK, Yoon YW, Chung JM. Comparison of three rodent neuropathic pain models. Exp Brain Res 1997;113:200-6.
14. Decosterd I, Woolf CJ. Spare nerve injury: an animal model of persistent peripheral neuropathic pain. Pain 2000;87:149-58.
15. Wang GM, Tian XB, Chen JP, Yang SB, Gao F, Yang H, et al. Prevention of neuropathic pain in an animal model of spare nerve injury following oral immunization with recombinant adenovirus serotype 5-mediated NR2B gene transfer. Gene Ther 2007;14:1681-7.
16. Eliav E, Herzberg U, Ruda MA, Bennett GJ. Neuropathic pain from an experimental neuritis of the rat sciatic nerve. Pain 1999;83:169–82.
17. Hofmann HA, Vry JD, Siegling A, Spreyer P, Denzer D. Pharmacological sensitivity and gene expression analysis of the tibial nerve injury model of neuropathic pain. Eur J Pharmacol 2003;470:17–25.
18. Colburn RW, Rickman AJ, DeLeo JA. The effect of site and type of nerve injury on spinal glial activation and neuropathic pain behavior. Exp Neurol 1999;157:289–304.
19. Tawfik VL, Regan MR, Haenggeli C, Lacroix-fralish ML, Nutile-McMenemy N, Perez N, et al. Propentofylline-induced astrocytes modulation leads to an alteration in glial glutamate promoter activation following spinal nerve transaction. Neuroscience 2008;152:1086-92.
20. Hu P, Bembrick AL, Keay KA, McLachlan EM. Immune cell involvement in dorsal root ganglia and spinal cord after chronic constriction or transaction of the rat sciatic nerve. Brain Behav Immun 2007;21:599-616.
21. DeLeo JA, Coombs DW, Willenbring S, Colburn RW, Fromm C, Wagner R, Twitchell BB. Characterization of a neuropathic pain model: sciatic cryoneurolysis in the rat. Pain 1994;56:9–16.
22. Willenbring S, Beauprie IG, DeLeo JA. Sciatic cryoneurolysis in rats: a model of sympathetically independent pain. Part 1: Effects of sympathectomy. Anesth Analg 1995;81:544–8.
23. Chacur M, Milligan ED, Gazda LS, Armstrong C, Wang H, Tracey KJ, et al. A new model of sciatic inflammatory neuritis (SIN): induction of unilateral and bilateral mechanical allodynia following acute unilateral peri-sciatic immune activation in rats. Pain 2001;94:231–44.
24. Benbouzid M, Pallage V, Rajalu M, Waltisperger E, Doridot S, Poisbeau P, et al. Sciatic nerve cuffing in mice: a model of sustained neuropathic pain. Eur J Pain 2007;12:591-9.
25. Courteix C, Bardin M, Chantelauze C, Lavarenne J, Eschalier A. Study of the sensitivity of the diabetes-induced pain model in rats to a range of analgesics. Pain 1994;57:153–60.
26. Mueller MJ. Identifying patients with diabetes mellitus who are at risk for lower-extremity complications: use of Semmes-Weinstein monofilaments. Phys Ther 1996;76:68–71.
27. Delaney A, Colvin LA, Fallon MT, Dalziel RG, Mitchell R, Fleetwood-Walker SM. Postherpetic neuralgia: from preclinical models to the clinic. Neurotherapeutics 2009;6:630-7.
28. Fleetwood-Walker SM, Quinn JP, Wallace C, Blackburn-Munro G, Kelly BG, Fiskerstrand CE, et al. Behavioral changes in the rat following infection with varicella-zoster virus. J Gen Virol 1999;80:2433–6.
29. Garry EM, Delaney A, Anderson HA, Sirinathsinghji EC, Clapp RH, Martin WJ, et al. Varicella-zoster virus induces neuropathic changes in rat dorsal root ganglia and behavioral reflex sensitization that is attenuated by gabapentin or sodium channel blocking drugs. Pain 2005;118:97–111.
30. Hasnie FS, Breuer J, Parker S, Wallace V, Blackbeard J, Lever IP, et al. Further characterization of a rat model of varicella zoster virus–associated pain: the relationship between mechanical hypersensitivity and anxiety-related behavior, and the influence of analgesic drugs. Neuroscience 2007;144:1495–508.
31. Calcutt NA, Jorge MC, Yaksh TL, Chaplan SR. Tactile allodynia and formalin hyperalgesia in streptozotocin-diabetic rats: effects of insulin, aldose reductase inhibition and lidocaine. Pain 1996;68:293-9.
32. Andersson DA, Filipović MR, Gentry C, Eberhardt M, Vastani N, Leffler A, et al. Streptozotocin stimulates the ion channel trpa1 directly: involvement of peroxynitrite. J Biol Chem 2015;290:15185-96.
33. Sima AA. Peripheral neuropathy in the spontaneously diabetic BB-Wistar-rat. An ultrastructural study. Acta Neuropathol 1980;51:223–7.
34. Schmidt RE, Green KG, Snipes LL, Feng D. Neuritic dystrophy and neuronopathy in Akita (Ins2(Akita)) diabetic mouse sympathetic ganglia. Exp Neurol 2009;216:207-18.
35. Joseph EK, Levine JD. Sexual dimorphism for protein kinase-Cε signaling in a rat model of vincristine-induced painful peripheral neuropathy. Neurosci 2003;119:831-8.
36. Linglu D, Yuxiang L, Yaqiong X, Ru Z, Lin M, Shaoju J, et al. Antinociceptive effect of matrine on vincristine-induced neuropathic pain model in mice. Neurol Sci 2014;35:815-21.
37. Muthuraman A, Jaggi AS, Singh N, Singh D. Ameliorative effects of amiloride and pralidoxime in chronic constriction injury and vincristine-induced painful neuropathy in rats. Eur J Pharmacol 2008;587:104-11.
38. Park HJ, Kim YH, Koh HJ, Park CS, Kang SH, Choi JH, et al. Analgesic effects of dexmedetomidine in vincristine-evoked painful neuropathic rats. J Korean Med Sci 2012;27:1411-7.
39. Jamieson SM, Liu JJ, Connor B, Draqunow M, McKeage MJ. Nucleolar enlargement, nuclear eccentricity and altered cell body immunostaining characteristics of large-sized sensory neurons following treatment of rats with paclitaxel. Neurotoxicology 2007;28:1092-9.
40. Jin HW, Flatters SJ, Xiao WH, Mulhern HL, Bennett GJ. Prevention of paclitaxel-evoked painful peripheral neuropathy by N-acetyl-L-carnitine: effects on axonal mitochondria, sensory nerve fiber terminal arbors, and cutaneous langerhans cells. Exp Neurol 2008;210:229-37.
41. Liu CC, Lu N, Cui Y, Yang T, Zhao ZQ, Xin WJ, et al. Prevention of paclitaxel-induced allodynia by minocycline: effect on loss of peripheral nerve fibers and infiltration of macrophages in rats. Mol Pain 2010;6:76.
42. Masocha W. Astrocyte activation in the anterior cingulate cortex and altered glutamatergic gene expression during paclitaxel-induced neuropathic pain in mice. Peer J 2015 22;3:e1350.
43. Ochi-ishi R, Nagata K, Inoue T, Tozaki-Saitoh H, Tsuda M, Inoue K. Involvement of the chemokine CCL3 and the purinoceptor P2X7 in the spinal cord in paclitaxel-induced mechanical allodynia. Mol Pain 2014;10:53.
44. Authier N, Gillet JP, Fialip J, Eschalier A, Coudore F. An animal model of nociceptive peripheral neuropathy following repeated cisplatin injections. Exp Neurol 2003;182:12-20.
45. Bianchi R, Brines M, Lauria G, Savino C, Gilardini A, Nicolini G, et al. Protective effect of erythropoietin and its carbamylated derivative in experimental cisplatin peripheral neurotoxicity. Clin Cancer Res 2006;12:2607-12.
46. Argyriou AA, Polychronopoulos P, Iconomou G, Chroni E, Kalofonos HP. A review on oxaliplatin-induced peripheral nerve damage. Cancer Treat Rev 2008;34:368-77.
47. Ling B, Authier N, balayssac, Eschalier A, Coudore F. Behavioral and pharmacological description of oxaliplatin-induced painful neuropathy in the rat. Pain 2007;128:225-34.
48. Ling B, Coudore-Civiale MA, Balayssac D, Eschalier A, Coudore F, Authier N. Behavioral and immunohistological assessment of painful neuropathy induced by single oxaliplatin injection in the rat. Toxicology 2007;234:176-84.
49. Fulfaro F, Casuccio A, Ticozzi C, Ripamonti C. The role of bisphosphonates in the treatment of painful metastatic bone disease: a review of phase III trials. Pain 1998;78:157–69.
50. Walker K, Medhurst SJ, Kidd BL, Glatt M, Bowes M, Patel S, et al. Disease modifying and anti-nociceptive effects of the bisphosphonate, zoledronic acid in a model of bone cancer pain. Pain 2002;100:219–29.
51. Schwei MJ, Honore P, Rogers SD, Salak-Johnson JL, Finke MP, Ramnaraine ML, et al. Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain. J Neurosci 1999;19:10886–97.
52. Melli G, Keswani SC, Fischer A, Chen W, Hoke A. Spatially distinct and functionally independent mechanisms of axonal degeneration in a model of HIV-associated sensory neuropathy. Brain 2006;129:1330–8.
53. Milligan ED, O,Connor KA, Nguyen KT, Armstrong CB, twining C, Gaykema RPA, et al. Intrathecal HIV-1 envelope glycoprotein gp120 induces enhanced pain states mediated by spinal cord proinflammatory cytokines. Neuroscience 2001;21:2808-19.
54. Verma S, Estanislao L, Simpson D. HIV-associated neuropathic pain: epidemiology, pathophysiology, and management. CNS Drugs 2005;19:325–34.
55. Wallace VC, Blackbeard J, Pheby T, Segerdahl AR, Davies M, Hansie F, et al. Pharmacological, behavioral and mechanistic analysis of HIV-1 gp 120 induced painful neuropathy. Pain 2007;133:47-63.
56. Youle M. Acetyl-L-carnitine in HIV-associated antiretroviral toxic neuropathy. CNS Drugs 2007;21:25-30.
57. Zhu Y, Antony JM, Martinez JA, Glerum DM, Brussee V, Hoke A, et al. Didanosine causes sensory neuropathy in HIV/AIDS animal model: impaired mitochondrial and neurotropic factor gene expression. Brain 2007;130:2011-23.
58. Bhangoo SK, Ren D, Miller RJ, Chan DM, Ripsch MS, Weiss C, et al. CXCR4 chemokine receptor signaling mediates pain hypersensitivity in association with antiretroviral toxic neuropathy. Brain Behav Immun 2007;21:581-91.
59. Youle M. Acetyl-L-carnitine in HIV-associated antiretroviral toxic neuropathy. CNS Drugs 2007;21:25-30.
Statistics
372 Views | 1958 Downloads
How to Cite
Thakur, S., and N. Srivastava. “AN UPDATE ON NEUROPATHIC PAIN MODELS”. International Journal of Pharmacy and Pharmaceutical Sciences, Vol. 8, no. 6, Apr. 2016, pp. 11-16, https://innovareacademics.in/journals/index.php/ijpps/article/view/11038.
Section
Review Article(s)